The US Justice Department filed a lawsuit to block a $570 million deal in the corporate travel market over antitrust concerns ...
Every investor in Silence Therapeutics plc ( NASDAQ:SLN) should be aware of the most powerful shareholder groups. The group holding the most number of shares in the company, around 44% to be precise, ...
Scientists have developed inhalable lung cancer therapeutics utilizing mucoadhesive proteinic nanoparticles.
Boost productivity with these essential Microsoft Outlook tips. Learn how to organize your inbox, automate tasks, and ...
Context Therapeutics (NASDAQ:CNTX – Get Free Report) was upgraded by Citizens Jmp to a “strong-buy” rating in a note issued ...
Lung cancer remains one of the deadliest cancers globally. Non-small cell lung cancer (NSCLC), which accounts for 85% of all lung cancer cases, is particularly challenging to treat due to difficulties ...
About Light Horse Therapeutics Light Horse Therapeutics emerged from the ... systematically interrogates complex signaling pathways in their native, cellular context to uncover unique sites of ...
Hosted on MSN1d
JMP Securities Initiates Coverage of Context Therapeutics (CNTX) with Market Outperform RecommendationFintel reports that on January 8, 2025, JMP Securities initiated coverage of Context Therapeutics (NasdaqCM:CNTX) with a ...
Sana Biotechnology, Inc. shares surge as a breakthrough in diabetes therapy sparks investor interest. Click for my updated ...
Hosted on MSN2d
Context Therapeutics Stock Jumps Pre-Market On Analyst's Near 4x Upside View: Retail Pins High Hopes TooShares of Context Therapeutics Inc. rose over 7% in Wednesday's pre-market trading after JMP Securities initiated coverage ...
Context Therapeutics (CNTX) has received a new Buy rating, initiated by JMP Securities analyst, Silvan Tuerkcan.Stay Ahead of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback